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Editorial
What to do with a pituitary incidentaloma?
“The frequency with which pituitary adenomas occur is a topic 
that has challenged endocrinologists for decades. From a 
research perspective, pituitary adenomas, irrespective of size or 
symptoms, are not unusual; indeed, they are very common.”
A pituitary incidentaloma is a previously 
unsuspected pituitary lesion that is discov-
ered on an imaging study performed for an 
unrelated reason [1].
The frequency with which pituitary 
adenomas occur is a topic that has chal-
lenged endocrinologists for decades. From 
a research perspective, pituitary adenomas, 
irrespective of size or symptoms, are not 
unusual; indeed, they are very common. 
As early as 1936, Russell Costello at the 
Mayo Clinic (Rochester, MN, USA) pub-
lished a remarkable study of the pitui-
tary glands of 1000 consecutive autopsy 
cases who had died of causes unrelated to 
pituitary disease [2]. Costello found that 
22.5% of pituitaries contained at least 
one adenoma and, while the adenoma 
size was not reported, some were large 
enough to occupy almost the entire gland. 
Pathological studies in the modern era 
have refined this information and suggest a 
prevalence rate of approximately 14.4% [3], 
although most of these are small (<2 mm 
diameter) and macroadenomas are rarely 
identified incidentally on autopsy [4].
“...pituitary adenomas do not 
always present in the same way 
and may be noted by chance 
during the investigation of 
other problems.”
However, for the clinical endocrinolo-
gist and epidemiologist, pituitary adeno-
mas present in a very different, real-life 
setting. While for many years clinically 
relevant pituitary adenomas were thought 
to be something of a rarity, more recent 
cross-sectional population studies have 
altered this view. In a study in the prov-
ince of Liège, Belgium, we found that 
proven pituitary adenomas with clinical 
signs/symptoms occurred with a preva-
lence of approximately one in 1000 of 
the general population [5], a rate that has 
also been largely replicated in the UK [6]. 
While these tumors presented classi-
cally with clinical correlates of hormonal 
abnormalities, pituitary adenomas do not 
always present in the same way and may be 
noted by chance during the investigation 
of other problems. 
The use of computed tomography 
(CT) and MRI has exploded over the 
last two decades, largely due to increased 
deployment of equipment in developed 
nations [7,101]. Indeed the latest interna-
tional statistics indicate that there are now 
on average 11.0 MRI scanners and 22.3 
CT scanners per million population among 
Organization for Economic Cooperation 
and Development countries [101]. This 
translates into 41.3 and 110.7 MRI and 
CT scans performed per 1000 of the popu-
lation per year, respectively [101]. In partic-
ular, neuroimaging of the head occurs very 
frequently in the emergency room setting, 
with the latest information showing that 
almost 7% of emergency room attendees in 
the USA receive a CT or MRI scan (most 
common reasons: trauma, headache and 
dizziness) [7,8]. Given that there are more 
than 117 million emergency room visits 
per annum in the USA, this indicates that 
a huge amount of acute neuroimaging of 
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the head occurs annually [8]. Against this background, the impor-
tance of pituitary tumors discovered incidentally on CT/MRI 
scans for other causes becomes very apparent. Data from meta-
ana lyses suggest that pituitary adenomas are present in over 22% 
of head CT/MRI scans [3]. Again, while many of these tumors are 
small, macroadenomas can be discovered incidentally in patients 
without suspected pituitary disease [9].
The discovery of a pituitary adenoma as an incidental finding 
on CT/MRI presents a number of challenges. First, the patient 
will be concerned about this finding and will seek information 
about what this means and what it implies. Such questions cannot 
be answered easily in the first instance based on a scan alone. The 
endocrinologist, on receiving the referral, must initially back-
track to determine whether any clinical symptoms or signs are 
present. Similarly, the issue of hormonal abnormalities needs to be 
explained to the patient and relevant testing planned. However, 
the appropriate follow-up needs to take into account initial clini-
cal findings and balance these against avoiding unnecessary over-
investigation of patients whose pituitary tumors are not likely to 
represent an immediate clinical challenge. Similarly, the tempta-
tion to pass off incidentalomas as clinically irrelevant has to be 
avoided, as this can miss the opportunity to undertake necessary 
interventions to improve or preserve the patient’s health. 
Optimal management of pituitary incidentalomas has been 
an open question for many years due to the lack of an agreed 
framework for investigation and follow-up. Thankfully, clini-
cians now have a new reference point with the publication of 
‘Pituitary Incidentaloma: An Endocrine Society Clinical Practice 
Guideline’ [1]. This evidence-based document (co-sponsored by 
the European Society of Endocrinology) used the Grades of 
Recommendation Assessment, Development and Evaluation 
(GRADE) system to describe the quality of the evidence and 
the strength of the recommendations made regarding evaluation, 
initial testing, therapy and follow-up testing of patients present-
ing with a pituitary incidentaloma. Importantly, the guideline 
document is accompanied by a patient information section to help 
explain the nature of incidentally discovered pituitary adenomas 
and their management [10].
It is practically useful to outline the recommendations from 
the beginning, at the initial referral of the patient. First, the 
patient presenting with a pituitary incidentaloma should have 
a history and physical examination, including a specific search 
for indications of hyper- and hypopituitarism. On a separate 
note, the initial clinical evaluation is also an ideal setting to 
enquire about family history in order to identify possible cases 
of multiple endocrine neoplasia 1 and newer conditions, such 
as familial isolated pituitary adenomas [11]. All patients with a 
pituitary incidentaloma should undergo clinical and laboratory 
assessments for hormonal hypersecretion and hyposecretion. At 
the initial visit, evaluation for hypersecretion should assess for 
prolactin, IGF-1 and cortisol (and/or adrenocorticotropic hor-
mone), although the choice of laboratory testing can be guided 
to some extent by clinical examination findings. For patients 
with small microadenomas (5 mm or less in diameter), routine 
screening for biochemical evidence of hypopituitarism is not 
felt to be mandatory, as lesions of this size are rarely associated 
with pituitary hypofunction. For larger microadenomas and all 
macroadenomas, the symptoms and clinical examination can 
guide hormonal testing choices, with particular attention needed 
regarding the challenges of accurately diagnosing growth hor-
mone deficiency. In terms of mass effects, the guidelines recom-
mend that all patients presenting with a pituitary incidentaloma 
that is abutting the optic nerves/chiasma on MRI have a formal 
visual field exam. This should be performed even if patients do 
not report visual symptoms, as unrecognized abnormalities have 
been reported in 5–15% of cases. A practical point is that patients 
with an incidentaloma that is diagnosed on CT scan should ide-
ally have an MRI (with fine cuts through the sella and with and 
without gadolinium if renal function allows) in order to more 
precisely appreciate the size of the tumor and its relations to 
adjacent structures. 
“...appropriate follow-up needs to take into 
account initial clinical findings and balance these 
against avoiding unnecessary over-investigation of 
patients whose pituitary tumors are not likely to 
represent an immediate clinical challenge.”
Once the incidentaloma has undergone initial investigation, 
patients who do not meet criteria for surgery should be followed-
up with clinical assessments and nonsurgical therapy as required. 
Practically, the removal of an asymptomatic pituitary incidenta-
loma that has no associated hormonal abnormalities or physical 
compressive effects is not warranted. The conservative approach 
for this form of follow-up remains to be fully defined as, to date, 
evidence in the literature is scanty. However, the following rec-
ommendations can be made for investigations in addition to 
clinical assessments: a 6-monthly MRI for macroincidentalomas 
and 12-monthly MRI for microincidentalomas. Thereafter, if no 
size increase is seen, macroincidentalomas should have an MRI 
every 12 months and microincidentalomas every 1–2 years. If 
the adenoma is seen to be stable for 3 years, then MRI can be 
undertaken more infrequently, although clinical examinations 
should be continued. Patients with macroincidentalomas should 
undergo hormonal testing for hypopituitarism 6 months after 
initial testing and then 12-monthly thereafter (microadenomas 
are less likely to cause hypopituitarism without an increase in size 
on MRI). Patients who develop new clinical signs and symptoms 
or increases in size on MRI should undergo testing as appropriate 
for hormonal abnormalities. For patients with tumor size increases 
on MRI that newly touch or compress the optic nerves/chiasma, 
visual fields should be retested. 
Patients with incidentalomas should be referred for surgery 
if they have a visual field defect caused by the pituitary tumor, 
other visual abnormalities caused by the tumor, a tumor that 
abuts or compresses the optic nerves for chiasma on MRI, 
pituitary apoplexy or hormonal hypersecretion (except prolac-
tinoma). In all cases, appropriate guidelines for the management 
of hyper secreting pituitary tumors should be followed. Patients 




surgery: growth of the incidentaloma, loss of hormonal function, 
patients considering pregnancy who have a tumor close to the 
optic chiasma and patients with unrelenting headache. 
The guideline document itself contains further discussion of 
all of these points and should be considered in full in order to tai-
lor the recommendations to the needs of each and every patient 
individually. Owing to the common occurrence of pituitary 
tumors in the population and the likely expanded use of MRI 
and CT of the head in the emergency setting or for investigation 
of non endocrine conditions, the challenges of how to manage 
the patient with a pituitary incidentaloma are likely to remain 
an everyday problem for the pituitary specialist. Hopefully, as 
prospective studies provide more information on the natural his-
tory of pituitary incidentalomas and their evolution, the recom-
mendations in this guideline can be further refined and adapted 
to improve patient outcomes.
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